Compound 948

Identifiers

Canonical SMILES:

OC(=O)CCCCNC(=O)[C@@H](N1[C@@H](c2ccc(Cl)cc2)C(=O)Nc2ccc(I)cc2C1=O)c1ccc(Cl)cc1

InChi:

InChI=1S/C28H24Cl2IN3O5/c29-18-8-4-16(5-9-18)24(26(37)32-14-2-1-3-23(35)36)34-25(17-6-10-19(30)11-7-17)27(38)33-22-13-12-20(31)15-21(22)28(34)39/h4-13,15,24-25H,1-3,14H2,(H,32,37)(H,33,38)(H,35,36)/t24-,25-/m0/s1

InChiKey:
```
ANYUCRJJKHLZON-DQEYMECFSA-N
```

External links

44176188

CHEMBL426321

23271195

External search

Bibliography (1)

Publication	Name
Parks DJ, LaFrance LV, Calvo RR, Milkiewicz KL, Marugán JJ, Raboisson P, Schubert C, Koblish HK, Zhao S, Franks CF, Lattanze J, Carver TE, Cummings MD, Maguire D, Grasberger BL, Maroney AC, Lu T. . Enhanced pharmacokinetic properties of 1,4-benzodiazepine-2,5-dione antagonists of the HDM2-p53 protein-protein interaction through structure-based drug design. Bioorganic & medicinal chemistry letters.	5

Publication

Name

Parks DJ, LaFrance LV, Calvo RR, Milkiewicz KL, Marugán JJ, Raboisson P, Schubert C, Koblish HK, Zhao S, Franks CF, Lattanze J, Carver TE, Cummings MD, Maguire D, Grasberger BL, Maroney AC, Lu T. . Enhanced pharmacokinetic properties of 1,4-benzodiazepine-2,5-dione antagonists of the HDM2-p53 protein-protein interaction through structure-based drug design. Bioorganic & medicinal chemistry letters.

Pharmacological data

Biochemical tests	Cellular tests	PK tests	Cytotoxicity tests
1	2	0	0

Targets

PPI family	Best activity	Diseases	MMoA
MDM2-Like / P53	6.06	cancer	Inhibition

Physicochemical filters

Descriptor	Lipinski's RO5	Veber	Pfizer's 3/75
MW	≤ 500 g/mol	-	-
AlogP	≤ 5	-	≤ 3
HBA	≤ 10	-	-
HBD	≤ 5	-	-
(HBA + HBD)	-	≤ 12	-
TPSA	-	≤ 140 Å²	≥ 75 Å²
RB	-	≤ 10	-

	Descriptor	Lipinski's RO5	Veber	Pfizer's 3/75
Compliance
MW	679.01 g/mol
HBA	8
HBD	3
HBA + HBD	11
AlogP	6.21
TPSA	115.81
RB	9

Radar chart

Short name	Threshold
MW	≤ 500 g/mol
AlogP	≤ 5
HBD	≤ 5
HBA	≤ 10
TPSA	≤ 140 Å²
RB	≤ 10
ArRing	≤ 4
Fsp3	≥ 0.4
R/S	≥ 1

PCA : iPPI-DB chemical space

PCA : Correlation circle

Efficiencies: iPPI-DB biplot LE versus LLE

Summary

Bibliographic ressources	Biochemical tests	Cellular tests	PK tests	Cytotoxicity tests
1	1	2	0	0

Pharmacological data

Bibliography	Name	Target	Assay type	Assay name	Cell line	Activity type	Activity
16600594	5	MDM2 Q00987	Biochemical assay	Fluorescence Polarization		pIC50 (half maximal inhibitory concentration, -log10)	6.06
16600594	5	MDM2 Q00987	Cellular assay	Proliferation assay	MCF7 mammary carcinoma cells	pIC50 (half maximal inhibitory concentration, -log10)	4.51
16600594	5	MDM2 Q00987	Cellular assay	Proliferation assay	MDA MB321 mammary carcinoma cells	pIC50 (half maximal inhibitory concentration, -log10)	4.05

Ta	Name	Drugbank ID
0.5298	4-[(4-bromo-2-{[(3R,5S)-3,5-dimethylpiperidin-1-yl]carbonyl}phenyl)amino]-4-oxobutanoic acid	DB08581
0.5263	Bentiromide	DB00522
0.5225	Ombitasvir	DB09296
0.5183	[(2S)-4-methyl-3-oxo-2,3,4,5-tetrahydro-1H-1,4-benzodiazepin-2-yl]acetic acid	DB08717
0.5159	4-chloro-N-(3-methoxypropyl)-N-[(3S)-1-(2-phenylethyl)piperidin-3-yl]benzamide	DB08344
0.5093	OPC-28326	DB05461
0.5091	Dexloxiglumide	DB04856
0.5085	Delparantag	DB12955
0.5062	Balicatib	DB12239
0.4922	CP-320626	DB03383
0.4896	Repaglinide	DB00912
0.4894	IMG-7289	DB15126
0.4885	AGG-523	DB15460
0.4870	Proglumide	DB13431
0.4863	2-{[4-(2-Acetylamino-2-pentylcarbamoyl-ethyl)-naphthalen-1-YL]-oxalyl-amino}-benzoic acid	DB01820